Limits...
Supplementation of a standardized extract from Phyllanthus emblica improves cardiovascular risk factors and platelet aggregation in overweight/class-1 obese adults.

Khanna S, Das A, Spieldenner J, Rink C, Roy S - J Med Food (2015)

Bottom Line: Lipid profile measurements demonstrated a significant decrease in calculated low-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein following 12 weeks of CAPROS supplementation when compared to averaged baseline visits.Circulatory high-sensitivity C reactive protein (hs-CRP) levels were significantly decreased after 12 weeks of supplementation.In addition, both ADP- and collagen-induced platelet aggregation was significantly downregulated following 12 weeks of supplementation.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, The Ohio State University Wexner Medical Center , Columbus, Ohio, USA .

ABSTRACT
The objective of this study (clinicaltrials.gov NCT01858376) was to determine the effect of oral supplementation of a standardized extract of Phyllanthus emblica (CAPROS(®)) on cardiovascular disease (CVD) risk factors in overweight adult human subjects from the US population. Overweight/Class-1 obese (body-mass index: 25-35) adult subjects received 500 mg of CAPROS supplement b.i.d for 12 weeks. The study design included two baseline visits followed by 12 weeks of supplementation and then 2 weeks of washout. At all visits, peripheral venous blood was collected in sodium citrate tubes. Lipid profile measurements demonstrated a significant decrease in calculated low-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein following 12 weeks of CAPROS supplementation when compared to averaged baseline visits. Circulatory high-sensitivity C reactive protein (hs-CRP) levels were significantly decreased after 12 weeks of supplementation. In addition, both ADP- and collagen-induced platelet aggregation was significantly downregulated following 12 weeks of supplementation. Overall, the study suggests that oral CAPROS supplementation may provide beneficial effects in overweight/Class-1 obese adults by lowering multiple global CVD risk factors.

Show MeSH

Related in: MedlinePlus

Significant reduction in platelet aggregation induced by adenosine diphosphate (ADP) after CAPROS supplementation. Platelet function was measured at baseline, 12 weeks (supplementation), and 14 weeks (2 weeks of washout). Representative platelet aggregation graphs at baseline (A) and after 12 weeks of supplementation (B). The extent of platelet aggregation in response to ADP plotted individual (C) and mean (D) in platelet-rich plasma (PRP). Values are mean±SEM. *denotes P<.05 (n=12) compared to baseline.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4390209&req=5

f3: Significant reduction in platelet aggregation induced by adenosine diphosphate (ADP) after CAPROS supplementation. Platelet function was measured at baseline, 12 weeks (supplementation), and 14 weeks (2 weeks of washout). Representative platelet aggregation graphs at baseline (A) and after 12 weeks of supplementation (B). The extent of platelet aggregation in response to ADP plotted individual (C) and mean (D) in platelet-rich plasma (PRP). Values are mean±SEM. *denotes P<.05 (n=12) compared to baseline.

Mentions: Platelet hyper-aggregability is associated with the risk factors for CVD. Platelet aggregation was measured in response to ADP, AA, and collagen agonists using an optical aggregometer. The aggregometer software analyzes the traces, reporting the results as maximum amplitude, slope, lag time, and area under the curve. Representative traces from baseline and post-supplementation aggregation measurements have been provided (Figs. 3 and 4). Both ADP- and collagen-induced platelet aggregation was significantly downregulated following 12 weeks of supplementation. For collagen-induced platelet aggregation, the response remained significantly lowered, compared to baseline, even during the washout period, demonstrating a sustained effect.


Supplementation of a standardized extract from Phyllanthus emblica improves cardiovascular risk factors and platelet aggregation in overweight/class-1 obese adults.

Khanna S, Das A, Spieldenner J, Rink C, Roy S - J Med Food (2015)

Significant reduction in platelet aggregation induced by adenosine diphosphate (ADP) after CAPROS supplementation. Platelet function was measured at baseline, 12 weeks (supplementation), and 14 weeks (2 weeks of washout). Representative platelet aggregation graphs at baseline (A) and after 12 weeks of supplementation (B). The extent of platelet aggregation in response to ADP plotted individual (C) and mean (D) in platelet-rich plasma (PRP). Values are mean±SEM. *denotes P<.05 (n=12) compared to baseline.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4390209&req=5

f3: Significant reduction in platelet aggregation induced by adenosine diphosphate (ADP) after CAPROS supplementation. Platelet function was measured at baseline, 12 weeks (supplementation), and 14 weeks (2 weeks of washout). Representative platelet aggregation graphs at baseline (A) and after 12 weeks of supplementation (B). The extent of platelet aggregation in response to ADP plotted individual (C) and mean (D) in platelet-rich plasma (PRP). Values are mean±SEM. *denotes P<.05 (n=12) compared to baseline.
Mentions: Platelet hyper-aggregability is associated with the risk factors for CVD. Platelet aggregation was measured in response to ADP, AA, and collagen agonists using an optical aggregometer. The aggregometer software analyzes the traces, reporting the results as maximum amplitude, slope, lag time, and area under the curve. Representative traces from baseline and post-supplementation aggregation measurements have been provided (Figs. 3 and 4). Both ADP- and collagen-induced platelet aggregation was significantly downregulated following 12 weeks of supplementation. For collagen-induced platelet aggregation, the response remained significantly lowered, compared to baseline, even during the washout period, demonstrating a sustained effect.

Bottom Line: Lipid profile measurements demonstrated a significant decrease in calculated low-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein following 12 weeks of CAPROS supplementation when compared to averaged baseline visits.Circulatory high-sensitivity C reactive protein (hs-CRP) levels were significantly decreased after 12 weeks of supplementation.In addition, both ADP- and collagen-induced platelet aggregation was significantly downregulated following 12 weeks of supplementation.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, The Ohio State University Wexner Medical Center , Columbus, Ohio, USA .

ABSTRACT
The objective of this study (clinicaltrials.gov NCT01858376) was to determine the effect of oral supplementation of a standardized extract of Phyllanthus emblica (CAPROS(®)) on cardiovascular disease (CVD) risk factors in overweight adult human subjects from the US population. Overweight/Class-1 obese (body-mass index: 25-35) adult subjects received 500 mg of CAPROS supplement b.i.d for 12 weeks. The study design included two baseline visits followed by 12 weeks of supplementation and then 2 weeks of washout. At all visits, peripheral venous blood was collected in sodium citrate tubes. Lipid profile measurements demonstrated a significant decrease in calculated low-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein following 12 weeks of CAPROS supplementation when compared to averaged baseline visits. Circulatory high-sensitivity C reactive protein (hs-CRP) levels were significantly decreased after 12 weeks of supplementation. In addition, both ADP- and collagen-induced platelet aggregation was significantly downregulated following 12 weeks of supplementation. Overall, the study suggests that oral CAPROS supplementation may provide beneficial effects in overweight/Class-1 obese adults by lowering multiple global CVD risk factors.

Show MeSH
Related in: MedlinePlus